OrbiMed’s Impax Laboratories, Inc. IPXL Stock Holding History

OrbiMed’s Portfolio IPXL Stock Details IPXL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q3	–	Sell	-150,000	Closed	-$6.89M	–	147
2015 Q2	$6.89M	Buy	150,000 +50,000	+50%	+$2.37M	0.06%	115
2015 Q1	$4.69M	Sell	100,000 -50,000	-33%	-$1.99M	0.04%	118
2014 Q4	$4.75M	Sell	150,000 -100,000	-40%	-$2.93M	0.05%	112
2014 Q3	$5.93M	Buy	+250,000	New	+$6.4M	0.06%	110

Other funds holding IPXL

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Hound Partners New York $799M AUM 9.54% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

NTC

North Tide Capital Boston, Massachusetts $469M AUM 6.57% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

OrbiMed's IPXL Position: Q4 2016 in Review

OrbiMed sold out of Impax Laboratories, Inc. (IPXL) in Q4 2016, closing a stake of 3,787,500 shares — an estimated $89.8M sold.

OrbiMed first reported a position in IPXL in Q2 2013 and held it in 14 quarters. The position peaked at $313M in Q1 2015. 198 funds tracked by Wall St. Rank hold IPXL as of Q4 2016.

OrbiMed reported no remaining Impax Laboratories, Inc. position as of Q4 2016 after selling out during the quarter.
OrbiMed sold 3,787,500 Impax Laboratories, Inc. shares in Q4 2016, an estimated $89.8M.
OrbiMed first reported a position in Impax Laboratories, Inc. in Q2 2013 and held it in 14 quarters.
OrbiMed's Impax Laboratories, Inc. position peaked at $313M in Q1 2015.
198 funds tracked by Wall St. Rank held Impax Laboratories, Inc. as of Q4 2016.

Based on OrbiMed's 13F filing for Q4 2016, filed 14 Feb 2017.